-
Reviews
Back to Reviews
-
Other Comments:
The authors have re-written their previous submission in a much more balanced way, and they now provide comparisons between 2 countries, namely Spain and The Netherlands, concerning the differences between naratriptan and rizatriptan for acute migraine, in terms of their cost effectiveness.
This article could now be of interest to a wider audience, and, although I still have several concerns as far as how its findings could have any impact on the current way acute migraine is treated, I recommend it to be published.
-
Competing interests:
No
-
Invited by the author to review this article? :
Yes -
Have you previously published on this or a similar topic?:
Yes
-
References:
Irritable bowel syndrome associated with mitral valve prolapse and autonomic and haemostatic abnormalities in children, adolescents and adults with migraine. Acta Neurol Scand. 2011 May;123(5):366-7. -
Experience and credentials in the specific area of science:
Gastroenterologist with special interest in neurodegenerative diseases and autoimmunity.
- How to cite: Zavos C .Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain [Review of the article 'Inter-Country Cost-Effectiveness Differences Between Naratriptan and Rizatriptan for the Acute Migraine in the Netherlands and Spain ' by Beas-morales, Pharmd A].WebmedCentral 2011;2(5):WMCRW00767
This paper contributes to the evaluation of cost-effectiveness differences between European countries.
The Authors of this paper are colleagues in the field of Health Economics, but they work in different institutions and locations. No other interests to be declared.
Yes
Yes
Hens M, Latorre-Martinez M, Vinuela-Alvarez D. Cost-effectiveness Evaluation of the Therapy with Naratriptan and Rizatriptan for Migraine in Spain . WebmedCentral ECONOMICS OF MEDICINE 2010;1(10):WMC00958
Neurologist. Expert on Health Economics.